Jundishapur Journal of Microbiology

Published by: Kowsar

Analysis of Naturally Occurring Resistant Mutations to Hepatitis C Virus NS3 Protease Inhibitors: A Preliminary Study in South of Iran

Mozhgan Afrasiabi 1 , Seyed Younes Hosseini 1 , * , Ramin Yaghobi 2 , * , Mohammad-Reza Fattahi 1 , Maryam Ardebili 1 and Mahboobeh Khodadad 1
Authors Information
1 Gastroenterohepatology Research Center (GEHRC), Shiraz University of Medical Sciences, Shiraz, IR Iran
2 Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
Corresponding Authors:
Article information
  • Jundishapur Journal of Microbiology: October 01, 2015, 8 (10); e24965
  • Published Online: October 29, 2015
  • Article Type: Research Article
  • Received: October 28, 2014
  • Revised: February 3, 2015
  • Accepted: February 28, 2015
  • DOI: 10.5812/jjm.24965

To Cite: Afrasiabi M, Hosseini S Y, Yaghobi R, Fattahi M, Ardebili M, et al. Analysis of Naturally Occurring Resistant Mutations to Hepatitis C Virus NS3 Protease Inhibitors: A Preliminary Study in South of Iran, Jundishapur J Microbiol. 2015 ; 8(10):e24965. doi: 10.5812/jjm.24965.

Copyright © 2015, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: Epidemiology of an emerging infection. Arch Iran Med. 2005; 8(2): 84-90
  • 2. Vermehren J, Sarrazin C. New HCV therapies on the horizon. Clin Microbiol Infect. 2011; 17(2): 122-34[DOI][PubMed]
  • 3. Courcambeck J, Bouzidi M, Perbost R, Jouirou B, Amrani N, Cacoub P, et al. Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations. Antivir Ther. 2006; 11(7): 847-55[PubMed]
  • 4. Kim AY, Timm J, Nolan BE, Reyor LL, Kane K, Berical AC, et al. Temporal dynamics of a predominant protease inhibitor-resistance mutation in a treatment-naive, hepatitis C virus-infected individual. J Infect Dis. 2009; 199(5): 737-41[DOI][PubMed]
  • 5. Parfieniuk A, Jaroszewicz J, Flisiak R. Specifically targeted antiviral therapy for hepatitis C virus. World J Gastroenterol. 2007; 13(43): 5673-81[PubMed]
  • 6. Kieffer TL, Kwong AD, Picchio GR. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimicrob Chemother. 2010; 65(2): 202-12[DOI][PubMed]
  • 7. Romano KP, Ali A, Royer WE, Schiffer CA. Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proc Natl Acad Sci U S A. 2010; 107(49): 20986-91[DOI][PubMed]
  • 8. Fields B, Knipe D, Howley PM. Fields virology. 2013;
  • 9. Mayhoub AS. Hepatitis C RNA-dependent RNA polymerase inhibitors: a review of structure-activity and resistance relationships; different scaffolds and mutations. Bioorg Med Chem. 2012; 20(10): 3150-61[DOI][PubMed]
  • 10. Le Guillou-Guillemette H, Vallet S, Gaudy-Graffin C, Payan C, Pivert A, Goudeau A, et al. Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy. World J Gastroenterol. 2007; 13(17): 2416-26[PubMed]
  • 11. Neau D, Jouvencel AC, Legrand E, Trimoulet P, Galperine T, Chitty I, et al. Hepatitis C virus genetic variability in 52 human immunodeficiency virus-coinfected patients. J Med Virol. 2003; 71(1): 41-8[DOI][PubMed]
  • 12. Vallet S, Gouriou S, Nousbaum JB, Legrand-Quillien MC, Goudeau A, Picard B. Genetic heterogeneity of the NS3 protease gene in hepatitis C virus genotype 1 from untreated infected patients. J Med Virol. 2005; 75(4): 528-37[DOI][PubMed]
  • 13. Lopez-Labrador FX, Moya A, Gonzalez-Candelas F. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. Antivir Ther. 2008; 13(4): 481-94[PubMed]
  • 14. Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology. 2008; 48(6): 1769-78[DOI][PubMed]
  • 15. Paolucci S, Fiorina L, Mariani B, Gulminetti R, Novati S, Barbarini G, et al. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naive patients. Virol J. 2013; 10: 355[DOI][PubMed]
  • 16. Zeminian LB, Padovani JL, Corvino SM, Silva GF, Pardini MI, Grotto RM. Variability and resistance mutations in the hepatitis C virus NS3 protease in patients not treated with protease inhibitors. Mem Inst Oswaldo Cruz. 2013; 108(1): 13-7[PubMed]
  • 17. Winters MA, Chary A, Eison R, Asmuth D, Holodniy M. Impact of highly active antiretroviral therapy on hepatitis C virus protease quasispecies diversity in HIV co-infected patients. J Med Virol. 2010; 82(5): 791-8[DOI][PubMed]
  • 18. Vicenti I, Rosi A, Saladini F, Meini G, Pippi F, Rossetti B, et al. Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy. J Antimicrob Chemother. 2012; 67(4): 984-7[DOI][PubMed]
  • 19. Colson P, Brouk N, Lembo F, Castellani P, Tamalet C, Gerolami R. Natural presence of substitution R155K within hepatitis C virus NS3 protease from a treatment-naive chronically infected patient. Hepatology. 2008; 47(2): 766-7[DOI][PubMed]
  • 20. Peres-da-Silva A, de Almeida AJ, Lampe E. Mutations in hepatitis C virus NS3 protease domain associated with resistance to specific protease inhibitors in antiviral therapy naive patients. Arch Virol. 2010; 155(5): 807-11[DOI][PubMed]
  • 21. Vallet S, Viron F, Henquell C, Le Guillou-Guillemette H, Lagathu G, Abravanel F, et al. NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5. Antivir Ther. 2011; 16(7): 1093-102[DOI][PubMed]
  • 22. Trevino A, de Mendoza C, Parra P, Rodriguez C, Madejon A, Plaza Z, et al. Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV-coinfected patients. Antivir Ther. 2011; 16(3): 413-6[DOI][PubMed]
  • 23. Alexopoulou A, Karayiannis P. Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals. Ann Gastroenterol. 2015; 28(1): 55-65[PubMed]
  • 24. Paolucci S, Fiorina L, Piralla A, Gulminetti R, Novati S, Barbarini G, et al. Naturally occurring mutations to HCV protease inhibitors in treatment-naive patients. Virol J. 2012; 9: 245[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments